Boryung, Lotus Pharma signs CDMO deal on anticancer injection
The company will provide the Taiwan-based firm's cytotoxic anticancer drugs in local market from 2026
By Dec 12, 2024 (Gmt+09:00)
Seoul-backed K-beauty brands set to make global mark
Australian infrastructure offers compelling opportunity: QIC
Europe looms large as K-beauty brands look to blue ocean; shares rise
NPS to lift stock holdings to 55% by 2030, raising risk appetite
NPS logs 0.87% return from first-quarter investment
South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and manufacturing organization (CDMO) to cytotoxic drugs.
Under the agreement, Boryung will manufacture an anticancer injection for Lotus.
The company plans to supply the agent to Lotus starting in 2026.
The product name will be disclosed by agreement between the two companies.
Boryung will manufacture the anticancer drug at its EU-GMP-certified plant in Yesan, South Chungcheong Province.
The facility, designed by Novo Nordisk Engineering (NNE), can produce 6 million vials annually.
Write to Ji-Hyun Lee at bluesky@hankyung.com
-
Aerospace & DefenseBoryung invests $10 million in Intuitive MachinesDec 06, 2024 (Gmt+09:00)
1 Min read -
Mergers & AcquisitionsEugene PE, KDB PE to acquire Boryung Biopharma for $231 millionJun 27, 2024 (Gmt+09:00)
2 Min read